Shattuck shares jump 11.47% intraday after SL-325 Phase I trial nearing completion and analyst upgrades from Wedbush and Needham.

Shattuck surged 11.47% intraday as the company announced its SL-325 Phase I clinical trial nearing completion by March 5, 2026, with data expected in Q2 and a Crohn’s disease Phase II trial planned for Q3. The company also reported Q4 2025 earnings exceeding estimates, with a narrower net loss and reduced R&D expenses, while Wedbush raised its price target to $8 and Needham initiated a buy rating with a $14 target.